All Oncology News

Most young breast cancer survivors can go on to have children despite the effects of their lifesaving treatment, a new study shows.

Defining the goals of a clinical team within a cancer program or oncology practice group, where the focus will be on maximizing QOL, may be difficult.

David A. Braun, MD, PhD, discusses the evolving treatment landscape of renal cell carcinoma.

The FDA has approved imetelstat (Rytelo) for select patients with myelodysplastic syndrome and transfusion-dependent anemia.

Mirvetuximab soravtansine led to an ORR of 51.9% in heavily pretreated patients with FRα-positive, platinum-sensitive ovarian cancer.

Teclistamab plus daratumumab and lenalidomide had a manageable safety profile in patients with transplant-ineligible, newly diagnosed multiple myeloma.

Eunice S. Wang, MD, discusses current unmet needs and efforts to move menin inhibitors into earlier lines of therapy in relapsed/refractory AML.

Florida Cancer Specialists & Research Institute, LLC announces the introduction of designated Disease SiteTeams for late-phase research & the subsequent formation of the FCS Disease Site Committee.

The combination of RP1 and nivolumab was safe and effective in patients with anti–PD-1-failed advanced melanoma.

Partition overall survival data indicated that nivolumab plus cabozantinib extended treatment-free survival vs sunitinib in advanced renal cell carcinoma.

Cretostimogene grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC according to the phase 2 CORE-001 trial.

Apalutamide/ADT maintains quality of life, demonstrates improved PSA progression-free survival in recurrent prostate cancer according to PRESTO trial.

Benjamin L. Maughan, MD, PharmD, discusses the implications of immuno-oncology and TKI agent combinations in clear cell and non–clear cell RCC.

Higher T-cell inflamed GEP values were positively associated with clinical outcomes for pembrolizumab plus axitinib in advanced clear cell RCC.

Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.

Retreatment with daratumumab-based regimens led to a similar ORR vs initial daratumumab treatment in relapsed/refractory myeloma.

Treatment cessation of enzalutamide-containing regimens in responding patients had no impact on QOL in biochemically recurrent nmHSPC.

Lenvatinib/pembrolizumab offered a significant benefit in terms of time to disease progression in all organs vs sunitinib in advanced RCC.

The European Commission granted orphan drug designation to UCART22 for acute lymphoblastic leukemia.

Lunresertib plus camonsertib received FDA fast track designation for select patients with platinum-resistant ovarian cancer.

Updated Analysis from Phase 1/2 MajesTEC-1 trial support the use of prophylactic tocilizumab to reduce the risk of cytokine release syndrome associated with outpatient administration of teclistamab.

Zyed Nabeel Zafar, MD, MPH, explores the nuances of postoperative considerations in pancreatic cancer treatment.

Brittany L. Bychkovsky, MD, MSc, and Lydia Pace, MD, MPH, explain approaches to breast cancer screening and considerations with the final USPSTF screening recommendations.

Olverembatinib showed antitumor activity in patients with TKI-resistant, SDH-deficient GISTs and paraganglioma.

TTFields therapy plus best supportive care increased time to first intracranial progression by 10.6 months in patients with NSCLC brain metastases.

Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma

Nivolumab plus ipilimumab and chemotherapy elicited a durable, long-term survival benefit vs chemotherapy alone in metastatic NSCLC.

A clinically meaningful but not statistically significant improvement in OS was observed with uproleselan plus chemotherapy vs chemotherapy alone in primary refractory AML.

Daratumumab plus VRd increased rates of MRD negativity in newly diagnosed, transplant-eligible multiple myeloma.

The European Medicines Agency’s CHMP has recommended the approval of frontline osimertinib plus chemotherapy for EGFR-mutated non–small cell lung cancer.